transient receptor potential cation channel, subfamily M, member 4
RGD ID:
620244
Description:
Exhibits calcium activated cation channel activity. Involved in several processes, including ion homeostasis; negative regulation of osteoblast differentiation; and regulation of blood circulation. Localizes to several cellular components, including Golgi apparatus; endoplasmic reticulum; and neuronal cell body. Biomarker of cardiac arrest. Human ortholog(s) of this gene implicated in erythrokeratodermia variabilis et progressiva 6 and progressive familial heart block type IB. Orthologous to human TRPM4 (transient receptor potential cation channel subfamily M member 4); INTERACTS WITH (+)-schisandrin B; 1-naphthyl isothiocyanate; 2,3,7,8-tetrachlorodibenzodioxine.
9-phenanthrol inhibits the reaction [Arsenic Trioxide results in increased expression of TRPM4 protein], tempol inhibits the reaction [Arsenic Trioxide results in increased expression of TRPM4 protein]
[Choline deficiency co-treated with Folic Acid deficiency co-treated with Methionine deficiency] results in increased expression of TRPM4 mRNA, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of TRPM4 mRNA
9-phenanthrol inhibits the reaction [Arsenic Trioxide results in increased expression of TRPM4 protein], tempol inhibits the reaction [Arsenic Trioxide results in increased expression of TRPM4 protein]
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of TRPM4 mRNA
[Choline deficiency co-treated with Folic Acid deficiency co-treated with Methionine deficiency] results in increased expression of TRPM4 mRNA, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of TRPM4 mRNA
[Choline deficiency co-treated with Folic Acid deficiency co-treated with Methionine deficiency] results in increased expression of TRPM4 mRNA, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of TRPM4 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of TRPM4 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of TRPM4 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin